Imaging Plaque Inflammation in Higher-Risk Patients: What Do We Know and What Are We Looking For?

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

1. 1.
   Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.CrossRefPubMedGoogle Scholar
2. 2.
   Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451(7181):953–7.CrossRefPubMedGoogle Scholar
3. 3.
   Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.CrossRefPubMedGoogle Scholar
4. 4.
   Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341–55.CrossRefPubMedCentralPubMedGoogle Scholar
5. 5.
   Cai J, Hatsukami TS, Ferguson MS, Kerwin WS, Saam T, Chu B, et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation. 2005;112(22):3437–44.CrossRefPubMedGoogle Scholar
6. 6.
   Motoyama S, Sarai M, Harigaya H, Anno H, Inoue K, Hara T, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54(1):49–57.CrossRefPubMedGoogle Scholar
7. 7.
   Obaid DR, Calvert PA, Gopalan D, Parker RA, Hoole SP, West NE, et al. Atherosclerotic plaque composition and classification identified by coronary computed tomography: assessment of computed tomography-generated plaque maps compared with virtual histology intravascular ultrasound and histology. Circ Cardiovasc Imaging. 2013;6(5):655–64.CrossRefPubMedGoogle Scholar
8. 8.
   Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92(3):657–71.CrossRefPubMedGoogle Scholar
9. 9.•
   Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. Jama. 2014;312(17):1754–63. Using coronary angiography, this study showed that nonobstructive CAD, compared with no apparent CAD, was associated with a significantly greater 1-year risk of MI and all-cause mortality.CrossRefPubMedGoogle Scholar
10. 10.
    Li H, Cybulsky MI, Gimbrone Jr MA, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb J Vasc Biol Am Heart Assoc. 1993;13(2):197–204.CrossRefGoogle Scholar
11. 11.
    Butcher MJ, Galkina EV. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol. 2012;3:44.CrossRefPubMedCentralPubMedGoogle Scholar
12. 12.
    Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989;86(8):2839–43.CrossRefPubMedCentralPubMedGoogle Scholar
13. 13.
    Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case–control study. Lancet. 2002;359(9324):2159–63.CrossRefPubMedGoogle Scholar
14. 14.
    Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103(4):491–5.CrossRefPubMedGoogle Scholar
15. 15.
    Schonbek U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD 40 and cardiovascular risk in women. Circulation. 2001;104:2266–8.CrossRefGoogle Scholar
16. 16.
    Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43.CrossRefPubMedGoogle Scholar
17. 17.
    Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–65.CrossRefPubMedGoogle Scholar
18. 18.
    Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. Jama. 2003;290(24):3199–206.CrossRefPubMedGoogle Scholar
19. 19.
    Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348(25):2500–7.CrossRefPubMedGoogle Scholar
20. 20.
    Graziosi M, Nanni C, Lorenzini M, Diemberger I, Bonfiglioli R, Pasquale F, et al. Role of (1)(8)F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. Eur J Nucl Med Mol Imaging. 2014;41(8):1617–23.CrossRefPubMedGoogle Scholar
21. 21.
    Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med Off Publ Soc Nucl Med. 1994;35(1):104–12.Google Scholar
22. 22.
    Babior BM. The respiratory burst of phagocytes. J Clin Invest. 1984;73(3):599–601.CrossRefPubMedCentralPubMedGoogle Scholar
23. 23.
    Rodriguez-Prados JC, Traves PG, Cuenca J, Rico D, Aragones J, Martin-Sanz P, et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol. 2010;185(1):605–14.CrossRefPubMedGoogle Scholar
24. 24.
    Satomi T, Ogawa M, Mori I, Ishino S, Kubo K, Magata Y, et al. Comparison of contrast agents for atherosclerosis imaging using cultured macrophages: FDG versus ultrasmall superparamagnetic iron oxide. J Nucl Med Off Publ Soc Nucl Med. 2013;54(6):999–1004.Google Scholar
25. 25.
    Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364(7):656–65.CrossRefPubMedCentralPubMedGoogle Scholar
26. 26.
    De Vries HE, Ronken E, Reinders JH, Buchner B, Van Berkel TJ, Kuiper J. Acute effects of oxidized low density lipoprotein on metabolic responses in macrophages. FASEB J Off Publ Fed Am Soc Exp Biol. 1998;12(1):111–8.Google Scholar
27. 27.•
    Lee SJ, Thien Quach CH, Jung KH, Paik JY, Lee JH, Park JW, et al. Oxidized low-density lipoprotein stimulates macrophage 18F-FDG uptake via hypoxia-inducible factor-1alpha activation through Nox2-dependent reactive oxygen species generation. J Nucl Med Off Publ Soc Nucl Med. 2014;55(10):1699–705. In this study the authors demonstrated that oxLDL, a key player in atherosclerotic inflammation, is a strong stimulator of macrophage (18)F-FDG uptake and glycolysis through upregulation of GLUT1 and hexokinase.Google Scholar
28. 28.
    Lederman RJ, Raylman RR, Fisher SJ, Kison PV, San H, Nabel EG, et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun. 2001;22(7):747–53.CrossRefPubMedGoogle Scholar
29. 29.
    Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, Gewirtz H, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 2005;12(3):294–301.CrossRefGoogle Scholar
30. 30.
    Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105(23):2708–11.CrossRefPubMedGoogle Scholar
31. 31.
    Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48(9):1818–24.CrossRefPubMedGoogle Scholar
32. 32.
    Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med Off Publ Soc Nucl Med. 2008;49(6):871–8.Google Scholar
33. 33.
    Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50(9):892–6.CrossRefPubMedGoogle Scholar
34. 34.
    Noh TS, Moon SH, Cho YS, Hong SP, Lee EJ, Choi JY, et al. Relation of carotid artery 18F-FDG uptake to C-reactive protein and Framingham risk score in a large cohort of asymptomatic adults. J Nucl Med Off Publ Soc Nucl Med. 2013;54(12):2070–6.Google Scholar
35. 35.
    Choi YS, Youn HJ, Chung WB, Hwang HJ, Lee DH, Park CS, et al. Uptake of F-18 FDG and ultrasound analysis of carotid plaque. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 2011;18(2):267–72.CrossRefGoogle Scholar
36. 36.
    Figueroa AL, Subramanian SS, Cury RC, Truong QA, Gardecki JA, Tearney GJ, et al. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging. 2012;5(1):69–77.CrossRefPubMedGoogle Scholar
37. 37.
    Graebe M, Pedersen SF, Hojgaard L, Kjaer A, Sillesen H. 18FDG PET and ultrasound echolucency in carotid artery plaques. J Am Coll Cardiol Img. 2010;3(3):289–95.CrossRefGoogle Scholar
38. 38.
    Graebe M, Pedersen SF, Borgwardt L, Hojgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2009;37(6):714–21.CrossRefGoogle Scholar
39. 39.••
    Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378(9802):1547–59. This trial suggests possible beneficial vascular effects of dalcetrapib, including the reduction in total vessel enlargement.CrossRefPubMedCentralPubMedGoogle Scholar
40. 40.
    Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, et al. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. Circ Cardiovasc Imaging. 2013;6(5):747–54.CrossRefPubMedGoogle Scholar
41. 41.
    Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med Off Publ Soc Nucl Med. 2009;50(10):1611–20.Google Scholar
42. 42.•
    Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. J Am Coll Cardiol Img. 2013;6(12):1250–9. This study proved that arterial FDG uptake, measured from routinely obtained PET/CT images, substantially improved incident CVD prediction beyond FRS and provided information on the potential timing of such events.Google Scholar
43. 43.
    Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol. 2012;71(5):709–18.CrossRefPubMedGoogle Scholar
44. 44.
    Fernandez-Ortiz A, Jimenez-Borreguero LJ, Penalvo JL, Ordovas JM, Mocoroa A, Fernandez-Friera L, et al. The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design. Am Heart J. 2013;166(6):990–8.CrossRefPubMedGoogle Scholar
45. 45.
    Muntendam P, McCall C, Sanz J, Falk E, Fuster V, High-Risk PI. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease—study design and objectives. Am Heart J. 2010;160(1):49–57. e1.CrossRefPubMedGoogle Scholar
46. 46.
    Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8.CrossRefPubMedGoogle Scholar
47. 47.
    Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002;106(23):2884–7.CrossRefPubMedGoogle Scholar
48. 48.
    Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48(9):1825–31.CrossRefPubMedGoogle Scholar
49. 49.
    Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62(10):909–17.CrossRefPubMedGoogle Scholar
50. 50.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35.CrossRefPubMedGoogle Scholar
51. 51.
    Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. J Am Coll Cardiol Img. 2011;4(10):1110–8.CrossRefGoogle Scholar
52. 52.
    Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49(17):1772–80.CrossRefPubMedGoogle Scholar
53. 53.
    Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99.CrossRefPubMedGoogle Scholar
54. 54.
    Tawakol A, Singh P, Rudd JH, Soffer J, Cai G, Vucic E, et al. Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging. J Am Coll Cardiol. 2014;63(1):86–8.CrossRefPubMedGoogle Scholar
55. 55.
    Investigators S, White HD, Held C, Stewart R, Tarka E, Brown R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–11.CrossRefGoogle Scholar
56. 56.
    O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. Jama. 2014;312(10):1006–15.CrossRefPubMedGoogle Scholar
57. 57.
    Cheng VY, Slomka PJ, Le Meunier L, Tamarappoo BK, Nakazato R, Dey D, et al. Coronary arterial 18F-FDG uptake by fusion of PET and coronary CT angiography at sites of percutaneous stenting for acute myocardial infarction and stable coronary artery disease. J Nucl Med Off Publ Soc Nucl Med. 2012;53(4):575–83.Google Scholar
58. 58.
    Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med Off Publ Soc Nucl Med. 2009;50(4):563–8.Google Scholar
59. 59.
    Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55(23):2527–35.CrossRefPubMedGoogle Scholar
60. 60.
    Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. J Am Coll Cardiol Img. 2010;3(4):388–97.CrossRefGoogle Scholar
61. 61.
    Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012;59(17):1539–48.CrossRefPubMedGoogle Scholar
62. 62.•
    Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-Fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383(9918):705–13. The authors in this study demonstrated the eficficacy of (18)F-NaF PET-CT imaging to identify and localise ruptured and high-risk coronary plaque.CrossRefPubMedGoogle Scholar
63. 63.
    Rominger A, Saam T, Vogl E, Ubleis C, la Fougere C, Forster S, et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med Off Publ Soc Nucl Med. 2010;51(2):193–7.Google Scholar
64. 64.•
    Tahara N, Mukherjee J, de Haas HJ, Petrov AD, Tawakol A, Haider N, et al. 2-Deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis. Nat Med. 2014;20(2):215–9. In this study,fluorodeoxymanose PET/CT imaging was used to characterize high risk atherosclerothic plaques with activated macrophages.CrossRefPubMedGoogle Scholar
65. 65.
    Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004;110(14):2032–8.CrossRefPubMedGoogle Scholar
66. 66.
    Beer AJ, Pelisek J, Heider P, Saraste A, Reeps C, Metz S, et al. PET/CT imaging of integrin alphavbeta3 expression in human carotid atherosclerosis. J Am Coll Cardiol Img. 2014;7(2):178–87.CrossRefGoogle Scholar